Author: Nathan Vardi
Rating:

The book chronicles the dramatic journey of the development of the BTK inhibitor, one of the most groundbreaking drugs for CLL (chronic lymphocytic leukemia). It delves into the drug’s creation by Pharmacyclics and Acerta Pharma, highlighting the intricacies of the development process. The author also explores the role of venture capital in the biotech industry, as well as the struggles among key company members, driven by their differing personalities. A captivating and insightful read!